CY1124273T1 - Μεθοδοι αγωγης καρκινου στο παγκρεας που περιλαμβανουν πακλιταξελη και γεμσιταβινη - Google Patents

Μεθοδοι αγωγης καρκινου στο παγκρεας που περιλαμβανουν πακλιταξελη και γεμσιταβινη

Info

Publication number
CY1124273T1
CY1124273T1 CY20211100585T CY211100585T CY1124273T1 CY 1124273 T1 CY1124273 T1 CY 1124273T1 CY 20211100585 T CY20211100585 T CY 20211100585T CY 211100585 T CY211100585 T CY 211100585T CY 1124273 T1 CY1124273 T1 CY 1124273T1
Authority
CY
Cyprus
Prior art keywords
gemcitabine
pancreatic cancer
cancer treatments
treatments including
including paclitaxel
Prior art date
Application number
CY20211100585T
Other languages
Greek (el)
English (en)
Inventor
Neil P. Desai
Markus Renschler
Original Assignee
Abraxis Bioscience, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51165317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124273(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abraxis Bioscience, Llc filed Critical Abraxis Bioscience, Llc
Publication of CY1124273T1 publication Critical patent/CY1124273T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
CY20211100585T 2013-01-11 2021-06-30 Μεθοδοι αγωγης καρκινου στο παγκρεας που περιλαμβανουν πακλιταξελη και γεμσιταβινη CY1124273T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361751820P 2013-01-11 2013-01-11
US201361752355P 2013-01-14 2013-01-14
US13/794,480 US9511046B2 (en) 2013-01-11 2013-03-11 Methods of treating pancreatic cancer
PCT/US2014/011145 WO2014110443A1 (en) 2013-01-11 2014-01-10 Methods of treating pancreatic cancer

Publications (1)

Publication Number Publication Date
CY1124273T1 true CY1124273T1 (el) 2022-11-25

Family

ID=51165317

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100585T CY1124273T1 (el) 2013-01-11 2021-06-30 Μεθοδοι αγωγης καρκινου στο παγκρεας που περιλαμβανουν πακλιταξελη και γεμσιταβινη

Country Status (25)

Country Link
US (3) US9511046B2 (OSRAM)
EP (1) EP2943192B9 (OSRAM)
JP (3) JP6342918B2 (OSRAM)
KR (1) KR102205710B1 (OSRAM)
CN (2) CN105025893A (OSRAM)
AU (1) AU2013203699B2 (OSRAM)
BR (1) BR112015016681A8 (OSRAM)
CA (1) CA2897589C (OSRAM)
CY (1) CY1124273T1 (OSRAM)
DK (1) DK2943192T3 (OSRAM)
ES (1) ES2878145T3 (OSRAM)
HK (1) HK1216853A1 (OSRAM)
HR (1) HRP20211062T1 (OSRAM)
HU (1) HUE056612T2 (OSRAM)
IL (2) IL239739A0 (OSRAM)
LT (1) LT2943192T (OSRAM)
MX (1) MX382017B (OSRAM)
NZ (2) NZ630230A (OSRAM)
PL (1) PL2943192T3 (OSRAM)
PT (1) PT2943192T (OSRAM)
RS (1) RS62076B1 (OSRAM)
SI (1) SI2943192T1 (OSRAM)
SM (1) SMT202100377T1 (OSRAM)
WO (1) WO2014110443A1 (OSRAM)
ZA (1) ZA201504877B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1585548T (lt) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Farmakologinių agentų kompozicijos ir įvedimo būdai
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
HUE038768T2 (hu) 2005-02-18 2018-11-28 Abraxis Bioscience Llc Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia
PT1931321T (pt) 2005-08-31 2019-05-14 Abraxis Bioscience Llc Composições compreendendo agentes farmacêuticos pouco hidrossolúveis e agentes antimicrobianos
ES2700074T3 (es) 2006-12-14 2019-02-13 Abraxis Bioscience Llc Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano
ES2435452T3 (es) * 2007-06-01 2013-12-19 Abraxis Bioscience, Llc Métodos y composiciones para tratar un cáncer recurrente
RS59896B1 (sr) 2009-04-15 2020-03-31 Abraxis Bioscience Llc Kompozicije nanočestica bez priona i postupci povezani sa njima
CN104784121A (zh) 2010-03-26 2015-07-22 阿布拉科斯生物科学有限公司 治疗肝细胞癌的方法
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
JP6031437B2 (ja) * 2010-06-07 2016-11-24 アブラクシス バイオサイエンス， エルエルシー 増殖性疾患を処置するための組み合わせ療法
KR102108959B1 (ko) 2011-04-28 2020-05-11 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
WO2013090634A1 (en) 2011-12-14 2013-06-20 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
NZ630213A (en) 2013-03-14 2017-05-26 Abraxis Bioscience Llc Methods of treating bladder cancer
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10751319B2 (en) 2015-06-04 2020-08-25 Crititech, Inc. Collection device and methods for use
CN116473964A (zh) 2015-06-29 2023-07-25 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
US10925852B2 (en) * 2015-06-30 2021-02-23 The Trustees Of Columbia University In The City Of New York Talc-bound compositions and uses thereof
EP3439635B1 (en) 2016-04-04 2020-12-09 Crititech, Inc. Formulations for solid tumor treatment
EP3595717A1 (en) * 2017-03-17 2020-01-22 Imclone, LLC Combination therapy for pancreatic cancer
SG10201913649TA (en) 2017-06-09 2020-03-30 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
KR102303762B1 (ko) 2017-06-14 2021-09-23 크리티테크, 인크. 폐 장애의 치료 방법
BR112020005814A2 (pt) 2017-10-03 2020-09-24 Crititech, Inc. administração local de partículas antineoplásicas em combinação com administração sistêmica de agentes imunoterapêuticos para o tratamento de câncer
RU2020134124A (ru) 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ
GB201908352D0 (en) * 2019-06-11 2019-07-24 Innovation Ulster Ltd Sonodynamic therapy
US20220332832A1 (en) * 2019-08-01 2022-10-20 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
CA3158764A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
US20230085602A1 (en) * 2020-02-04 2023-03-16 Swedish Orphan Biovitrum AB (publ ) Pdac treatment regimen
KR20250154513A (ko) * 2023-03-09 2025-10-28 미네암리타 테라퓨틱스, 엘엘씨 췌장암 치료용 약물 조합
CN117099681B (zh) * 2023-08-28 2024-07-05 南京农业大学 一种利用紫杉醇加倍玉米单倍体的方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
AU673057B2 (en) 1993-02-22 1996-10-24 Abraxis Bioscience, Llc Methods for (in vivo) delivery of biologics and compositionsuseful therefor
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP1023050B1 (en) 1997-06-27 2013-09-25 Abraxis BioScience, LLC Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CA2369740A1 (en) 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents
HK1045646A1 (zh) 1999-05-21 2002-12-06 Abraxis Bioscience, Llc 蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
KR20190034694A (ko) 2002-12-09 2019-04-02 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
LT1585548T (lt) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Farmakologinių agentų kompozicijos ir įvedimo būdai
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
AU2012201568B2 (en) 2005-02-18 2014-07-31 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
HUE038768T2 (hu) 2005-02-18 2018-11-28 Abraxis Bioscience Llc Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
KR20080000682A (ko) * 2005-04-29 2008-01-02 코산 바이오사이언시즈, 인코포레이티드 17-ａａｇ 또는 17-ａｇ, 또는 이들의 프로드럭을 사용한다발성 골수종의 치료 방법
PT1931321T (pt) 2005-08-31 2019-05-14 Abraxis Bioscience Llc Composições compreendendo agentes farmacêuticos pouco hidrossolúveis e agentes antimicrobianos
CA2620389C (en) 2005-08-31 2014-06-17 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2007297339A (ja) * 2006-04-29 2007-11-15 Torii Yakuhin Kk 癌を治療又は検査するための医薬
EP2056812A1 (en) 2006-08-31 2009-05-13 Abraxis BioScience, LLC Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
ES2700074T3 (es) 2006-12-14 2019-02-13 Abraxis Bioscience Llc Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano
BRPI0808635B1 (pt) 2007-03-07 2022-06-07 Abraxis Bioscience, Llc Uso de uma composição farmacêutica compreendendo nanopartículas que compreendem rapamicina ou um seu derivado e uma proteína veículo, composição para uso em um método de tratamento de câncer em um indivíduo, forma de dosagem unitária para o referido tratamento, e kit
WO2008137148A2 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
ES2435452T3 (es) 2007-06-01 2013-12-19 Abraxis Bioscience, Llc Métodos y composiciones para tratar un cáncer recurrente
WO2009126401A1 (en) 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
RU2010145529A (ru) 2008-04-10 2012-05-20 АБРАКСИС БАЙОСАЙЕНС ЭлЭлСи (US) Композиции гидрофобных производных таксана и их применение
WO2009126934A2 (en) * 2008-04-11 2009-10-15 Seattle Genetics, Inc. Detection and tratment of pancreatic, ovarian and other cancers
AU2009324464B2 (en) 2008-12-11 2016-05-05 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
GB0900555D0 (en) 2009-01-14 2009-02-11 Topotarget As New methods
WO2010105172A1 (en) 2009-03-13 2010-09-16 Abraxis Bioscience, Llc Combination therapy with thiocolchicine derivatives
US20130195983A1 (en) 2009-04-10 2013-08-01 Neil P. Desai Nanoparticle formulations and uses thereof
RS59896B1 (sr) 2009-04-15 2020-03-31 Abraxis Bioscience Llc Kompozicije nanočestica bez priona i postupci povezani sa njima
JP5886191B2 (ja) * 2009-05-28 2016-03-16 アブラクシス バイオサイエンス， エルエルシー 化学療法への反応を予測するための２つの抗ｓｐａｒｃ抗体の使用
KR20120053052A (ko) 2009-08-25 2012-05-24 아브락시스 바이오사이언스, 엘엘씨 헤지호그 억제제 및 탁산의 나노입자 조성물로의 조합 요법
JP2011079788A (ja) * 2009-10-08 2011-04-21 Oita Univ 膵癌に対する選択的膵動脈制癌剤注入療法と全身化学療法との併用療法、およびそれに使用する膵癌治療薬
AU2011204405B2 (en) * 2010-01-05 2015-06-18 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
CN104784121A (zh) 2010-03-26 2015-07-22 阿布拉科斯生物科学有限公司 治疗肝细胞癌的方法
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
WO2011121453A2 (en) 2010-03-30 2011-10-06 Clavis Pharma Asa Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
MY188911A (en) 2010-06-02 2022-01-13 Abraxis Bioscience Llc Methods of treating bladder cancer
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
JP6031437B2 (ja) 2010-06-07 2016-11-24 アブラクシス バイオサイエンス， エルエルシー 増殖性疾患を処置するための組み合わせ療法
KR102108959B1 (ko) 2011-04-28 2020-05-11 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
WO2013090634A1 (en) 2011-12-14 2013-06-20 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US20140199404A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
HK1218506A1 (zh) 2013-02-11 2017-02-24 阿布拉科斯生物科学有限公司 治療黑素瘤的方法
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
AU2014228386B2 (en) 2013-03-13 2018-11-29 Abraxis Bioscience, Llc Methods of treatment of pediatric solid tumor
NZ630213A (en) 2013-03-14 2017-05-26 Abraxis Bioscience Llc Methods of treating bladder cancer
US20170202782A1 (en) 2014-04-06 2017-07-20 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
US20180064679A1 (en) 2015-03-05 2018-03-08 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
JP2018527308A (ja) 2015-06-29 2018-09-20 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物のためのバイオマーカー
HK1247093A1 (zh) 2015-06-29 2018-09-21 阿布拉科斯生物科学有限公司 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法
CN116473964A (zh) 2015-06-29 2023-07-25 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
US20170181988A1 (en) 2015-12-23 2017-06-29 Cipla Limited Methods for the treatment of bladder cancer

Also Published As

Publication number Publication date
EP2943192B1 (en) 2021-05-12
EP2943192B9 (en) 2021-09-29
LT2943192T (lt) 2021-08-10
US9511046B2 (en) 2016-12-06
DK2943192T3 (da) 2021-07-05
PL2943192T3 (pl) 2022-01-24
EP2943192A1 (en) 2015-11-18
SI2943192T1 (sl) 2021-09-30
JP6342918B2 (ja) 2018-06-13
ZA201504877B (en) 2016-10-26
US20170020824A1 (en) 2017-01-26
ES2878145T3 (es) 2021-11-18
HUE056612T2 (hu) 2022-02-28
KR102205710B1 (ko) 2021-01-21
JP2016505018A (ja) 2016-02-18
BR112015016681A2 (pt) 2017-07-11
JP2018087235A (ja) 2018-06-07
RS62076B1 (sr) 2021-07-30
CA2897589C (en) 2021-03-02
HK1216853A1 (zh) 2016-12-09
SMT202100377T1 (it) 2022-01-10
MX382017B (es) 2025-03-11
AU2013203699A1 (en) 2014-10-30
IL239739A0 (en) 2015-08-31
IL272905A (en) 2020-04-30
JP6697017B2 (ja) 2020-05-20
JP2019081790A (ja) 2019-05-30
BR112015016681A8 (pt) 2019-10-22
CA2897589A1 (en) 2014-07-17
CN105025893A (zh) 2015-11-04
KR20150103745A (ko) 2015-09-11
MX2015008898A (es) 2015-10-14
US9855220B2 (en) 2018-01-02
US20140199403A1 (en) 2014-07-17
HRP20211062T1 (hr) 2021-12-24
US20180153820A1 (en) 2018-06-07
NZ630230A (en) 2017-09-29
US10328031B2 (en) 2019-06-25
PT2943192T (pt) 2021-07-16
EP2943192A4 (en) 2016-06-01
NZ734971A (en) 2018-12-21
CN109793728A (zh) 2019-05-24
WO2014110443A1 (en) 2014-07-17
AU2013203699B2 (en) 2016-09-08

Similar Documents

Publication Publication Date Title
CY1124273T1 (el) Μεθοδοι αγωγης καρκινου στο παγκρεας που περιλαμβανουν πακλιταξελη και γεμσιταβινη
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
CY1124926T1 (el) Νανοσωματιδια που περιλαμβανουν σιρολιμους και μια αλβουμινη για χρηση στη θεραπεια ογκων απο επιθηλιοειδη κυτταρα
MX389667B (es) Antagonistas de unión al eje pd-1 y taxanos para usarse en el tratamiento de cáncer.
CY1121907T1 (el) Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων
CY1122478T1 (el) Συνθεσεις που περιεχουν anti-cd38 αντισωματα και λεναλιδομιδη
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2015010312A (es) Metodos para tratamiento del melanoma.
MX2015008888A (es) Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
NI201200175A (es) Métodos de tratamiento de cáncer de vejiga
CY1122813T1 (el) Διαλυτος cd33 για την αγωγη μυελοδυσπλαστικων συνδρομων (μds)
MX2016001236A (es) Anticuerpos anti-fgfr2iiib afucosilados.
MX2016004441A (es) Tratamiento del cancer con una combinacion de plinabulina y taxano.
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
CY1121821T1 (el) Θεραπεια συνδυασμου για την αγωγη του καρκινου των ωοθηκων
CY1123019T1 (el) Σπειροκυκλικες ενωσεις
MX2018003301A (es) Inhibidores de pcna.
CY1122998T1 (el) Μεθοδοι και συνθεσεις για την αντιμετωπιση της καταθλιψης χρησιμοποιωντας κυκλοβενζαπρινη
ECSP14011792A (es) Inhibidores de iap
PH12017501879A1 (en) Methods for treating cancer
CY1122403T1 (el) Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης
CY1117674T1 (el) Χρηση παραγωγων των orvinol και thevinol ως θεραπευτικη αγωγη στην καταχρηση αλκοολ και φαρμακων